*August 2024* Currently, afatinib (Gilotrif) is the only approved treatment for advanced non–small cell lung cancer (NSCLC) with atypical EGFR mutations, including S768I, L861Q, and G719X. However, its effectiveness is limited. Cohort C of the CHRYSALIS-2 study (NCT04077463) investigated the combination of amivantamab (Rybrevant) and lazertinib (Leclaza), which has proven efficacy in more…

*October 2024* The clinical benefits of immune checkpoint inhibitor (ICI)-based treatments in treating individuals with advanced EGFR-mutated non-small-cell lung cancer (NSCLC) who have progressed on EGFR tyrosine-kinase inhibitors (TKIs) remain controversial. We aimed to review the literature to comprehensively investigate the individual and comparative clinical outcomes of various ICI-based treatment strategies…

*December 2024* Hello. I'm Mark Kris, from Memorial Sloan Kettering, speaking today about the use of chemotherapy with a targeted therapy, particularly in patients with EGFR and ALK mutations. I'd like to compare and contrast the thoughts about using chemotherapy in the postoperative adjuvant setting vs in the stage IV setting. I think the clearest…

*August 2024* Patients with EGFR-mutated non-small cell lung cancer (NSCLC) benefit from treatment with tyrosine kinase inhibitors (TKI) targeting EGFR. Despite improvements in patient care, especially with the 3rd generation TKI osimertinib, disease relapse is observed in all patients. Among the various processes involved in TKI resistance, epithelial-to-mesenchymal transition (EMT) is…

*September 2024* This recorded event will delve into cutting-edge advancements in the diagnosis and treatment of Leptomeningeal Metastases (LM). Greg Fuller, MD, PhD, from The University of Texas MD Anderson Cancer Center and Plus Therapeutics, will kick off the session with an extensive exploration of the neuropathological aspects of Leptomeningeal…

*August 2024* On August 19, 2024, the Food and Drug Administration approved lazertinib (Lazcluze, Janssen Biotech, Inc.) in combination with amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon…

*November 2024* Abstract INTRODUCTION EGFR tyrosine kinase inhibitors have been a standard treatment for patients with non-small cell lung cancer (NSCLC) have sensitive EGFR mutations. This study showed final analysis survival data, biomarkers and resistance mechanisms of osimertinib plus bevacizumab or osimertinib monotherapy in previously untreated patients with advanced EGFR-positive non-squamous NSCLC. METHODS…

*August 2024* Zongertinib (BI 1810631), an investigational oral therapy, was granted breakthrough therapy designation (BTD) from the FDA. China’s Center for Drug Evaluation (CDE) also granted a BTD for this agent in adult patients with advanced, unresectable or metastatic non–small cell lung cancer (NSCLC) whose tumors have activating HER2 mutations and who…

*August 2024* A fast track designation has been granted to Deltacel (KB-GDT-01) in combination with low-dose radiation therapy by the FDA. This indication is for patients with metastatic non–small cell lung cancer (NSCLC) who have progressed on 2 or more prior lines of standard-of-care therapy. The agent is currently undergoing…

*August 2024* The discovery of EGFR as a driver mutation and the development of medications to take advantage of this mutation changed the treatment of non-small cell lung cancer (NSCLC) forever. Not only did it vastly improve outcomes for patients with this subset of cancers, it opened the door for…